Tumor necrosis factor-alpha and the cytokine network in psoriasis;Fator de necrose tumoral-alfa e a rede de citocinas na psoriase

Anais Brasileiros de Dermatologia

Volumn 87, Issue 5, 2012, Pages 673-683

  Brotas, Arles Martins ^a   Cunha, José Marcos Tellas ^b   Lago, Eduardo Henrique Jorge ^c   Machado, Cristiane Chaves Nascentes ^b   Carneiro, Sueli Coelho da Silva ^d  

^a Marcilio Dias Naval Hospital HNMD Hospital Naval Marcílio Dias   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c CEUMA UNIVERSITY   (Brazil)

^d STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Cytokines; Psoriasis; Tumor necrosis factor alpha

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ACANTHOSIS; ARTICLE; CYTOKINE PRODUCTION; DISEASE COURSE; HUMAN; HYPERKERATOSIS; HYPERPLASIA; LYMPHOCYTIC INFILTRATION; PARAKERATOSIS; PSORIASIS;

CELL COMMUNICATION; CYTOKINES; HUMANS; KERATINOCYTES; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867766823     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/S0365-05962012000500001     Document Type: Article

References (73)

1. Steinhoff M, Luger TA. The skin cytokine network. In: Bos JD, editor. Skin Immune System. Cutaneous Immunology and Clinical Immunodermatology. 3rd ed. Boca Raton, Florida: CRC Press; 2005. p.349-72.
2. Abbas AK, Lichtman AH. Citocinas. In: Abbas AK. Imunologia celular e molecular. 5 ed. São Paulo: Elsevier; 2005. p. 251-82.
3. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996;17:138-46.
4. Salgame P, Abrams JS, Clayberger C, Goldstein H, Convit J, Modlin RL, et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science. 1991;254:279-82.
5. Sampaio SAP, Rivitti EA. Imunopatologia cutânea. In: Sampaio SAP, Rivitti EA Dermatologia. 3 ed. São Paulo: Artes Médicas; 2007. p.45-76.
6. Najarian DJ, Gottlieb AB. Connections between psoriasis and Crohn's disease. J Am Acad Dermatol. 2003;48:805-21.
7. Salomão Barreto MA, Vianna SV, Brotas A, Pessanha F, Carneiro SCS. Terapia biológica no tratamento da psoríase e da artrite psoriásica. In: 60 Congresso Brasileiro de Dermatologia; 2005; Brasília-DF, Brasil. Rio de Janeiro: Anais Brasileiros de Dermatologia; 2005. p.202.
8. Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, May LT, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A. 1989;86:6367-71.
9. Barker JN, Sarma V, Mitra RS, Dixit VM, Nickoloff BJ. Marked synergism between tumor necrosis factor-alpha and interferon-gamma in regulation of keratinocytederived adhesion molecules and chemotactic factors. J Clin Invest. 1990;85:605-8.
10. Gomi T, Shiohara T, Munakata T, Imanishi K, Nagashima M. Interleukin 1 alpha, tumor necrosis factor alpha, and interferon gamma in psoriasis. Arch Dermatol. 1991;127:827-30.
11. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol. 1993;101:701-5.
12. Vollmer S, Menssen A, Trommler P, Schendel D, Prinz JC. T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol. 1994;24:2377-82.
13. Olaniran AK, Baker BS, Paige DG, Garioch JJ, Powles AV, Fry L. Cytokine expression in psoriatic skin lesions during PUVA therapy. Arch Dermatol Res. 1996;288:421-5.
14. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity. 2004:21:241-54.
15. Chung Y, Yang X, Chang S H, Ma L, Tian Q, Dong C. Expression and regulation of IL-22 in the IL-17-producing CD4+ T lymphocytes. Cell Res. 2006:16:902-7.
16. Sanchez APG. Imunopatogênese da psoríase. An Bras Dermatol. 2010;85:747-9.
17. Boyd AS, Neldner KH. The isomorphic response of Koebner. Int J Dermatol. 1990;29:401-10.
18. Yano S, Banno T, Walsh R, Blumenberg M. Transcriptional responses of human epidermal keratinocytes to cytokine interleukin-1. J Cell Physiol. 2008;214:1-13.
19. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol. 2010;6:232-41.
20. Sanmiguel JC, Olaru F, Li J, Mohr E, Jensen LE. Interleukin-1 regulates keratinocyte expression of T cell targeting chemokines through interleukin-1 receptor associated kinase-1 (IRAK1) dependent and independent pathways. Cell Signal. 2009;21:685-94.
21. Zalewska A, Głowacka E, Wyczółkowska J, Tchórzewski H, Narbutt J, Sysa-Je{ogonek}drzejowska A. Interleukin 6 and 8 Levels in Plasma and Fibroblast Cultures in Psoriasis. Mediators Inflamm. 2006;2006:81767.
22. Castells-Rodellas A, Castell JV, Ramirez-Bosca A, Nicolas JF, Valcuende-Cavero F, Thivolet J. Interleukin-6 in normal skin and psoriasis. Acta Derm Venereol. 1992;72:165-8.
23. Goodman WA, Levine AD, Massari JV, Sugiyama H, McCormick TS, Cooper KD. IL-6 Signaling in Psoriasis Prevents Immune Suppression by Regulatory T Cells1. J Immunol. 2009;183;3170-6.
24. Alenius GM, Eriksson C, Rantapää Dahlqvist S. Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis? Clin Exp Rheumatol. 2009;27:120-3.
25. Cordiali-Fei P, Ardigò M, Mastroianni A, Giuliani A, D' Agosto G, Bordignon V, et al. Serum cytokines and bioumoral immunological characterization of psoriatic patients in long term etanercept treatment. Int J Immunopathol Pharmacol. 2008;21:643-9.
26. Koshiba S, Ichimiya S, Nagashima T, Tonooka A, Kubo T, Kikuchi T, et al. Tonsillar crypt epithelium of palmoplantar pustulosis secretes interleukin-6 to support B-cell development via p63/p73 transcription factors. J Pathol. 2008;214:75-84.
27. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171-86.
28. Pereira FSM. Perfil Lipídico dos pacientes com psoríase do Hospital Universitário Clementino Fraga Filho da Universidade Federal do Rio de Janeiro [dissertação]. Rio de Janeiro (RJ): Universidade Federal do Rio de Janeiro
29. Duarte GV, Follador I, Cavalheiro CM, Silva TS, Oliveira Mde F. Psoriasis and obesity: literature review and recommendations for management. An Bras Dermatol. 2010;85:355-60
30. Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 2002;51:3391-9.
31. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-α, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003;278:45777-84.
32. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes. Diabetologia. 2005;48:1038-50.
33. Beljaards RC, Van Beek P, Nieboer C, Stoof TJ, Boorsma DM. The expression of interleukin-8 receptor in untreated and treated psoriasis. Arch Dermatol Res. 1997;289:440-3.
34. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005;2005:273-9.
35. Ferran M, Galván AB, Giménez-Arnau A, Pujol RM, Santamaría-Babi LF. Production of interleukin 8 by circulating CLA+ T cells with skin tropism in patients with psoriasis and in healthy controls. Actas Dermosifiliogr. 2010;101:151-5
36. Czelusta AJ, Evans T, Arany I, Tyring SK. A guide to immunotherapy of genital warts: focus on interferon and imiquimod. BioDrugs. 1999;11:319-32.
37. Boraschi D, Censini S, Bartalini M, Tagliabue A. Regulation of arachidonic acid metabolism in macrophages by immune and nonimmune interferons. J Immunol. 1985;135:502-5.
38. Yurci A, Guven K, Torun E, Gursoy S, Baskol M, Akgun H, et al. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C. Eur J Gastroenterol Hepatol. 2007;19:811-5.
39. Horev A, Halevy S. New-onset psoriasis following treatment with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C. Isr Med Assoc J. 2009;11:760-1.
40. Ketikoglou I, Karatapanis S, Elefsiniotis I, Kafiri G, Moulakakis A. Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. Eur J Dermatol. 2005;15:107-9.
41. Fierlbeck G, Rassner G, Muller C. Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations. Arch Dermatol. 1990;126:351-5.
42. Gaspari AA. Mechanism of action and other potential roles of an immune response modifier. Cutis. 2007;79(4 Suppl):36-45.
43. Blauvelt A. New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF-β1. Expert Rev Dermatol. 2007;2:69-78.
44. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 2007;8:345-50.
45. Chen Y, Langrish CL, McKenzie B, Joyce-Shaikh B, Stumhofer JS, McClanahan T, et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest. 2006;116:1317-26.
46. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal development pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature. 2006;441:235-38.
47. Chen Z, Tato CM, Muul L, Laurence A, O'Shea JJ. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum. 2007;56:2936-46.
48. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278:1910-4.
49. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin-17 producing CD4+ effector T cells develop via a lineage district from the T helper type 1 and 2 lineages. Nat. Immunol. 2005;6:1123-32.
50. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammations by producing inerleukin-17. Nat Immunol. 2005;6:1133-41.
51. Ma HL, Liang S, Li J, Napierata L, Brown T, Benoit S, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 2008;118:597-607.
52. Cosmi L, De Palma R, Santarlasci V, Maggi L, Capone M, Frosali F, et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med. 2008;205:1903-16.
53. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118-28.
54. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994;96:146-51.
55. Mussi A, Bonifati C, Carducci M, D'Agosto G, Pimpinelli F, D'Urso D, et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents. 1997;11:115-8.
56. Sagawa Y, Shiohara T, Imanishi K, Nagashima M. Is sustained production of tumor necrosis factor-alpha relevant to the development of pustular psoriasis? Dermatology. 1993;187:81-3.
57. Seishima M, Takemura M, Saito K, Kitajima Y. Increased serum soluble Fas, tumor necrosis factor alpha and interleukin 6 concentrations in generalized pustular psoriasis. Dermatology. 1998;196:371-2.
58. Nickoloff BJ. The cytokine network in psoriasis. Arch Dermatol. 1991;127:871-84.
59. Partsch G, Steiner G, Leeb BF, Dunky A, Bröll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol. 1997;24:518-23.
60. Wollina U, Konrad H. Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-alpha antibody. J Eur Acad Dermatol Venereol. 2002;16:127-9.
61. Weaver AL, Kavanaugh A, Beutler BA, Burmester GR, O'Dell JR. The evolution of biologic DMARD therapy in rheumatoid arthritis management. Medscape [Internet]. [cited 2010 Jul 10]. Available from: http://www.medscape.com/viewprogram/2109
62. Shear MJ, Turner FC, Perrault A. Chemical treatment of tumors. V. Isolation of the hemorrhage-producing fraction from Serratia marcescens (Bacillus prodigiosus) culture filtrate. J Natl Cancer Inst. 1943;4:81-97.
63. Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem. 1988;57:505-18.
64. Tracey KJ, Vlassara H, Cerami A. Cachectin/tumour necrosis factor. Lancet. 1989;1:1122-6.
65. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992;10:411-52.
66. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334:1717-25.
67. Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK, 3rd. Biology of tumor necrosis factor-alpha-implications for psoriasis. Exp Dermatol. 2004;13:193-222.
68. Magalhães RF, Biral AC, Pancoto JA, Donadi EA, Mendes CT Jr, Magna LA, et al. Human leukocyte antigen (HLA) and single nucleotide polymorphisms (SNPs) tumor necrosis factor (TNF)-alpha-238 and-308 as genetic markers of susceptibility to psoriasis and severity of the disease in a long-term follow-up Brazilian study. Int J Dermatol. 2010;49:1133-40.
69. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1986;234:470-4.
70. Neuner P, Urbanski A, Trautinger F, Möller A, Kirnbauer R, Kapp A, et al. Increased IL-6 production by monocytes and keratinocytes in patients with psoriasis. J Invest Dermatol. 1991;97:27-33.
71. Gottlieb AB. Psoriasis. Immunopathology and immunomodulation. Dermatol Clin. 2001;19:649-57, viii.
72. Sirsjö A, Karlsson M, Gidlöf A, Rollman O, Törmä H. Increased expression of inducible nitric oxide synthase in psoriatic skin and cytokine-stimulated cultured keratinocytes. Br J Dermatol. 1996;134:643-8.
73. Schwarzenberger K, Udey MC. Contact allergens and epidermal proinflammatory cytokines modulate Langerhans cell E-cadherin expression in situ. J Invest Dermatol. 1996;106:553-8.